Who is on it, and how far along Every drug ChEMBL records acting on NTRK1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Small molecule 6 Protein or peptide 1 Other 1 Approved3 Entrectinib Entrectinib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials26 Larotrectinib Larotrectinib SponsorBayer ModalitySmall molecule ActionInhibitor Open trials20 Cenegermin Cenegermin SponsorDompé Farmaceutici ModalityProtein or peptide ActionAgonist Open trials4 Phase 23 Taletrectinib Taletrectinib SponsorNuvation Bio ModalitySmall molecule ActionInhibitor Open trials6 Altiratinib Altiratinib SponsorOno Pharmaceutical ModalitySmall molecule ActionInhibitor Open trials0 Selitrectinib Selitrectinib SponsorBayer ModalitySmall molecule ActionInhibitor Open trials0 Phase 12 AZD-6918 AZD-6918 SponsorAstraZeneca Pharmaceuticals ModalityOther ActionInhibitor Open trials0 CEP-2563 CEP-2563 SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Neurotrophic tyrosine kinase receptor inhibitor; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Entrectinib Phase 2 Not yet recruiting St. Jude Children's Research Hospital Nov 4, 2026 Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study Larotrectinib Early phase 1 Not yet recruiting Olivia Newton-John Cancer Research Institute Oct 30, 2026 A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy Larotrectinib Phase 1 / Phase 2 Not yet recruiting M.D. Anderson Cancer Center Sep 28, 2026 Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations Entrectinib Phase 2 Not yet recruiting Shanghai Zhongshan Hospital Sep 21, 2026 Molecularly Tailored Therapy in Advanced Pancreatic Cancer Larotrectinib Phase 2 Not yet recruiting Herlev Hospital Sep 3, 2026 Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib Taletrectinib Phase 1 Not yet recruiting Nuvation Bio Inc. Aug 3, 2026 An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED Cenegermin Phase 3 Recruiting Dompé Farmaceutici S.p.A Apr 9, 2026 Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Cenegermin Phase 3 Recruiting Dompé Farmaceutici S.p.A Mar 6, 2026 Study on the Mechanism of Acquired Resistance of Entrectinib Entrectinib — Recruiting Fudan University Sep 30, 2025 Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression Entrectinib, Taletrectinib — Not yet recruiting Innovent Biologics (Suzhou) Co. Ltd. Sep 30, 2025 Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) Taletrectinib Phase 3 Recruiting Nuvation Bio Inc. Sep 4, 2025 Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study Cenegermin Not applicable Not yet recruiting London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Jul 18, 2025 Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Larotrectinib Phase 4 Not yet recruiting Fujian Medical University Jun 8, 2025 Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases Taletrectinib — Recruiting Innovent Biologics (Suzhou) Co. Ltd. Jun 6, 2025 DOMPE -MT Neurotrophic Keratitis Cenegermin Phase 4 Active, not recruiting Toyos Clinic Apr 27, 2025 Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC Entrectinib — Not yet recruiting National Cancer Center, China Nov 19, 2024 Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Entrectinib Phase 2 Not yet recruiting Peking University Shenzhen Hospital Nov 18, 2024 Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. Larotrectinib Phase 2 Recruiting Sun Yat-sen University Aug 21, 2024 A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Taletrectinib Phase 3 Recruiting Nuvation Bio Inc. Aug 21, 2024 Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib Phase 2 Recruiting St. Jude Children's Research Hospital Jul 30, 2024 Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Entrectinib, Larotrectinib Phase 2 Recruiting West China Hospital Jul 1, 2024 Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) Larotrectinib Phase 2 Active, not recruiting National Cancer Institute (NCI) Apr 30, 2024 A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer Larotrectinib Phase 4 Recruiting Fudan University Jan 8, 2024 Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Taletrectinib Phase 2 Active, not recruiting Nuvation Bio Inc. Jun 9, 2021
Show all 24Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3559684 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-22. ChEMBL and Open Targets